Medicine and Dentistry
Hepatocellular Carcinoma
100%
Patient
100%
Clinical Trial
100%
Monotherapy
50%
Development
33%
Bevacizumab
33%
Angiogenesis Inhibitor
33%
Nivolumab
33%
Sorafenib
33%
Atezolizumab
33%
Therapeutic Procedure
33%
Diseases
16%
Drug Therapy
16%
Biological Marker
16%
CTLA-4
16%
Supportive Care
16%
Liver Function
16%
Local Therapy
16%
Tumor Regression
16%
Chemotherapeutic Agent
16%
Standing
16%
Drug
16%
Ipilimumab
16%
Tumor Immunity
16%
Pembrolizumab
16%
Arm
16%
Survival
16%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Immune Checkpoint Inhibitor
100%
Monotherapy
50%
Angiogenesis Inhibitor
33%
Bevacizumab
33%
Sorafenib
33%
Nivolumab
33%
Programmed Death-Ligand 1
33%
Diseases
16%
Biological Marker
16%
Neoplasm
16%
Drug
16%
Tumor Regression
16%
Ipilimumab
16%
Pembrolizumab
16%
Survival
16%
Cytotoxic T Lymphocyte Antigen 4
16%